1-7 of 7
Seth A. Wander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T. Coates, Bogang Wu, Rachel O. Abelman, Laura Spring, Beverly Moy, Phoebe Ryan, Mark N. Melkonyan, Ann Partridge, Dejan Juric, Jeffrey Peppercorn, Heather Parsons, Seth A. Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven J. Isakoff, Sara M. Tolaney, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2917–2924.
https://doi.org/10.1158/1078-0432.CCR-24-0428
Published: 15 July 2024
View article titled, Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cracking the Genomic Code of CDK4/6 Inhibitor Resistance

Seth A. Wander, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2008–2010.
https://doi.org/10.1158/1078-0432.CCR-23-3413
Published: 15 May 2024
View article titled, Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
Open the PDF for Cracking the Genomic Code of CDK4/6 Inhibitor Resistance in another window
Journal Articles

Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 821–830.
https://doi.org/10.1158/1078-0432.CCR-21-2947
Published: 01 March 2022
View article titled, Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
Open the PDF for Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities in another window
Journal Articles

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3404–3413.
https://doi.org/10.1158/1078-0432.CCR-20-3444
Published: 15 June 2021
View article titled, Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Open the PDF for Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

Pingping Mao, Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco, Pedro Exman, Seth A. Wander, Adrienne G. Waks, Utthara Nayar, Jon Chung, Samuel Freeman, Orit Rozenblatt-Rosen, Vincent A. Miller, Federica Piccioni, David E. Root, Aviv Regev, Eric P. Winer, Nancy U. Lin, Nikhil Wagle
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5974–5989.
https://doi.org/10.1158/1078-0432.CCR-19-3958
Published: 13 November 2020
View article titled, Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Open the PDF for Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer
Open the PDF for <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies

Seth A. Wander, Dekuang Zhao, Joyce M. Slingerland
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 12–18.
https://doi.org/10.1158/1078-0432.CCR-10-0752
Published: 04 January 2011
View article titled, p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies
Open the PDF for p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies in another window